Haematology 2018

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Lesokhin A et al J Clin Oncol. 2016 Aug 10;34(23):2698-704.

• Phase 1 study, 81 patients with B-cell malignancies

• (NHL n = 31, including DLBCL [ n = 11], and FL [ n = 10]) other B cell NHL, T cell lymphoma ( n = 23), and multiple myeloma ( n = 27); treated with Nivolumab 3 mg/kg (NCT01592370).

• All patients had received prior systemic treatment regimens (median 3; range, 1–12).